JP6184952B2 - 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 - Google Patents

抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 Download PDF

Info

Publication number
JP6184952B2
JP6184952B2 JP2014525434A JP2014525434A JP6184952B2 JP 6184952 B2 JP6184952 B2 JP 6184952B2 JP 2014525434 A JP2014525434 A JP 2014525434A JP 2014525434 A JP2014525434 A JP 2014525434A JP 6184952 B2 JP6184952 B2 JP 6184952B2
Authority
JP
Japan
Prior art keywords
cells
hodgkin
antibody
bendamustine
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014525434A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014525926A5 (cg-RX-API-DMAC7.html
JP2014525926A (ja
Inventor
アメルスドルファー，ユタ
シュタイドル，シュテファン
ウィンデルリッヒ，マーク
クローン，スザンヌ
ロイックジャー，リサ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2014525926A publication Critical patent/JP2014525926A/ja
Publication of JP2014525926A5 publication Critical patent/JP2014525926A5/ja
Application granted granted Critical
Publication of JP6184952B2 publication Critical patent/JP6184952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014525434A 2011-08-16 2012-08-14 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法 Active JP6184952B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161523861P 2011-08-16 2011-08-16
EP11177658 2011-08-16
US61/523,861 2011-08-16
EP11177658.9 2011-08-16
US201261647539P 2012-05-16 2012-05-16
US61/647,539 2012-05-16
US201261654097P 2012-06-01 2012-06-01
US61/654,097 2012-06-01
PCT/EP2012/065906 WO2013024097A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Publications (3)

Publication Number Publication Date
JP2014525926A JP2014525926A (ja) 2014-10-02
JP2014525926A5 JP2014525926A5 (cg-RX-API-DMAC7.html) 2015-10-01
JP6184952B2 true JP6184952B2 (ja) 2017-08-23

Family

ID=47714801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014525434A Active JP6184952B2 (ja) 2011-08-16 2012-08-14 抗ｃｄ１９抗体とナイトロゲンマスタードとの併用療法

Country Status (24)

Country Link
US (3) US20140255427A1 (cg-RX-API-DMAC7.html)
EP (2) EP4062936A1 (cg-RX-API-DMAC7.html)
JP (1) JP6184952B2 (cg-RX-API-DMAC7.html)
KR (3) KR20200058583A (cg-RX-API-DMAC7.html)
CN (1) CN103732252B (cg-RX-API-DMAC7.html)
AU (1) AU2012296907B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013033919B1 (cg-RX-API-DMAC7.html)
CA (2) CA2841875C (cg-RX-API-DMAC7.html)
CY (1) CY1125122T1 (cg-RX-API-DMAC7.html)
DK (1) DK2744515T3 (cg-RX-API-DMAC7.html)
ES (1) ES2909722T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220228T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058350T2 (cg-RX-API-DMAC7.html)
IL (1) IL230293B (cg-RX-API-DMAC7.html)
LT (1) LT2744515T (cg-RX-API-DMAC7.html)
MX (1) MX354479B (cg-RX-API-DMAC7.html)
PL (1) PL2744515T3 (cg-RX-API-DMAC7.html)
PT (1) PT2744515T (cg-RX-API-DMAC7.html)
RS (1) RS63238B1 (cg-RX-API-DMAC7.html)
RU (1) RU2625222C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201606785UA (cg-RX-API-DMAC7.html)
SI (1) SI2744515T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200159T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013024097A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2951427A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
CA2986175A1 (en) * 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
EP3436070A4 (en) 2016-03-29 2019-11-27 University of Southern California AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS
MA45124B1 (fr) * 2016-05-30 2021-05-31 Morphosys Ag Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
IL266216B2 (en) * 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL266892B2 (en) 2016-12-02 2025-10-01 Univ Southern California Artificial immune receptors and methods of using them
PL3630177T3 (pl) * 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
KR20240131370A (ko) * 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
DE69909459T2 (de) * 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
CN100358577C (zh) * 1999-05-07 2008-01-02 杰南技术公司 抗体在制备治疗哺乳动物自身免疫病的试剂中的用途
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
AR054094A1 (es) 2004-11-05 2007-06-06 Cephalon Inc Tratamientos de cancer
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
AU2007285976B2 (en) * 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2662340C (en) 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
EP2405937A4 (en) * 2009-01-16 2012-06-20 Glaxosmithkline Llc CANCER THERAPY USING A COMBINATION OF BENDAMUSTIN AND AN ANTIBODY AGAINST CD20
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
RU2012109451A (ru) * 2009-08-14 2013-09-27 Роше Гликарт Аг Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
EP2501237A1 (en) * 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
EP4062936A1 (en) 2022-09-28
CN103732252B (zh) 2017-11-10
PT2744515T (pt) 2022-05-19
EP2744515A1 (en) 2014-06-25
PL2744515T3 (pl) 2022-05-30
BR112013033919A2 (pt) 2017-12-19
HUE058350T2 (hu) 2022-07-28
US20140255427A1 (en) 2014-09-11
CN103732252A (zh) 2014-04-16
CA2841875A1 (en) 2013-02-21
WO2013024097A1 (en) 2013-02-21
RU2014103492A (ru) 2015-09-27
CA2841875C (en) 2021-11-02
DK2744515T3 (da) 2022-03-28
ES2909722T3 (es) 2022-05-10
AU2012296907B2 (en) 2017-01-05
MX354479B (es) 2018-03-07
IL230293B (en) 2019-01-31
US20240366756A1 (en) 2024-11-07
HRP20220228T1 (hr) 2022-05-13
KR20140064873A (ko) 2014-05-28
NZ617770A (en) 2016-01-29
SMT202200159T1 (it) 2022-05-12
US20200353077A1 (en) 2020-11-12
RS63238B1 (sr) 2022-06-30
SI2744515T1 (sl) 2022-05-31
LT2744515T (lt) 2022-04-25
MX2013014933A (es) 2014-04-16
CY1125122T1 (el) 2024-12-13
BR112013033919B1 (pt) 2022-11-16
SG10201606785UA (en) 2016-10-28
JP2014525926A (ja) 2014-10-02
EP2744515B1 (en) 2022-02-09
CA3137321A1 (en) 2013-02-21
KR102115203B1 (ko) 2020-05-28
RU2625222C2 (ru) 2017-07-12
KR20190107749A (ko) 2019-09-20
KR20200058583A (ko) 2020-05-27

Similar Documents

Publication Publication Date Title
AU2022202796B2 (en) Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof
US20240366756A1 (en) Combinations and uses thereof
JP6114273B2 (ja) 抗−ｃｄ１９抗体とプリン類似体の併用治療
US12194095B2 (en) Combinations and uses thereof
JP2014525926A5 (cg-RX-API-DMAC7.html)
JP2014525925A5 (cg-RX-API-DMAC7.html)
KR102500868B1 (ko) 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도
AU2012296907A1 (en) Combination therapy with an anti - CD19 antibody and a nitrogen mustard
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
NZ617770B2 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170426

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170726

R150 Certificate of patent or registration of utility model

Ref document number: 6184952

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250